BIT Capital GmbH Boosts Stock Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

BIT Capital GmbH lifted its stake in Immunocore Holdings plc (NASDAQ:IMCR) by 182.7% in the fourth quarter, HoldingsChannel reports. The firm owned 67,840 shares of the company’s stock after acquiring an additional 43,840 shares during the quarter. BIT Capital GmbH’s holdings in Immunocore were worth $2,001,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of IMCR. Wellington Management Group LLP boosted its stake in shares of Immunocore by 10.5% in the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock valued at $219,430,000 after buying an additional 668,382 shares during the period. Two Sigma Advisers LP raised its holdings in Immunocore by 65.6% in the third quarter. Two Sigma Advisers LP now owns 757,700 shares of the company’s stock valued at $23,587,000 after acquiring an additional 300,200 shares in the last quarter. Primecap Management Co. CA lifted its stake in Immunocore by 8.0% in the fourth quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company’s stock worth $78,722,000 after acquiring an additional 196,530 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Immunocore by 25.0% during the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after acquiring an additional 109,206 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Immunocore by 7,437.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company’s stock valued at $2,872,000 after purchasing an additional 91,033 shares during the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Immunocore

In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the acquisition, the director now directly owns 2,144,060 shares in the company, valued at $63,721,463.20. This represents a 60.40 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 9.10% of the company’s stock.

Immunocore Trading Up 0.5 %

IMCR opened at $29.47 on Thursday. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -31.02 and a beta of 0.79. Immunocore Holdings plc has a 52 week low of $27.19 and a 52 week high of $66.00. The business’s 50 day moving average is $30.00 and its two-hundred day moving average is $31.01. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Analysts Set New Price Targets

IMCR has been the subject of several recent analyst reports. Morgan Stanley reaffirmed an “equal weight” rating and set a $35.00 price objective on shares of Immunocore in a research report on Friday, March 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 price target on shares of Immunocore in a report on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research report on Wednesday, March 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $65.64.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.